» Authors » Pierre Denys

Pierre Denys

Explore the profile of Pierre Denys including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 113
Citations 1354
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Carpentier V, Weiss N, Salem J, Joussain C, Levy J, Mariani L, et al.
Ann Phys Rehabil Med . 2025 Mar; 68(3):101924. PMID: 40081132
Background: Botulinum toxin is commonly used in the treatment of neurological disorders. Although neurological complications predominate and can lead to respiratory failure or death, no observational studies have specifically described...
2.
Perennou D, Burger H, Paik N, Brochard S, Coudeyre E, Denys P, et al.
Ann Phys Rehabil Med . 2025 Feb; 68(1):101950. PMID: 39947813
No abstract available.
3.
Welniarz A, Levy J, Even A, Denys P, Joussain C
Fr J Urol . 2025 Feb; 35(5):102865. PMID: 39929365
Introduction: The aim of this study was to determine psychometric properties of Ice Water Test (IWT) to predict the appearance of a detrusor activity in patients with persistent neurogenic acontractile...
4.
Lallemant-Dudek P, Guillaud-Bataille M, Hentzen C, Joussain C, Pichon B, Robain G, et al.
Eur J Neurol . 2024 Dec; 32(1):e70003. PMID: 39704400
Background: The aim of this study was to characterize hereditary spastic paraplegias (HSP) patients' urodynamic profiles and development of bladder symptoms. Methods: This is a multicentric retrospective study which included...
5.
Le B, Even A, Welniarz A, Chartier Kastler E, Denys P, Joussain C
World J Urol . 2024 Dec; 43(1):27. PMID: 39666027
Purpose: The artificial urinary sphincter (AUS) remains the gold standard to treat stress urinary incontinence related to sphincter insufficiency in patients with neurogenic lower urinary tract dysfunction (NLUTD). This study...
6.
Ruffion A, Karam P, Forestier A, Denys P
Toxins (Basel) . 2024 Oct; 16(10). PMID: 39453198
In recent decades, intradetrusor injections of botulinum toxin A (BoNT-A) have been widely applied to treat incontinence in both idiopathic overactive bladder (iOAB) and neurogenic detrusor overactivity incontinence (NDOI). This...
7.
Duchaine F, Espagnacq M, Bensmail D, Regaert C, Denys P, Levy J
J Epidemiol Popul Health . 2024 Aug; 72(5):202773. PMID: 39111117
Introduction: French Public Health Insurance gathers health, demographic and economic data based on codes from the 10th version of the international classification of diseases (ICD-10), specific nomenclature for each health-care...
8.
Leilaz A, Joussain C, Denys P, Bensmail D, Levy J
Toxins (Basel) . 2024 Jun; 16(6). PMID: 38922146
As multiple indications for botulinum toxin injections (BTIs) can coexist for neurological patients, there are to date no description of concomitant injections (CIs) to treat both spasticity and neurogenic detrusor...
9.
Baya-Arnaud B, Welniarz A, Even A, Denys P, Dinh A, Joussain C
Fr J Urol . 2024 Jun; 34(14):102653. PMID: 38823483
Objective: The indication for prophylactic antibiotic therapy during cystomanometry to prevent urinary tract infection (UTI) has long been recommended. However, limited data support this approach. Our study aims to evaluate...
10.
Mailho C, Peyronnet B, De Seze M, Even A, Perrouin-Verbe M, Amarenco G, et al.
Neurourol Urodyn . 2024 Mar; 43(4):811-817. PMID: 38451038
Introduction: Neurogenic detrusor overactivity (NDO) has a major impact on patients' quality of life and can lead to upper urinary tract complications. Intradetrusor botulinum toxin type A injections are administered...